Published in Clin Liver Dis on February 01, 2007
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol (2008) 3.16
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol (2009) 1.41
Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol (2011) 1.35
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res (2010) 1.10
Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch (2011) 1.07
Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci (2010) 1.05
Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes (2013) 1.01
Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. PLoS One (2010) 1.01
Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol (2010) 1.01
Garlic-Derived S-Allylmercaptocysteine Ameliorates Nonalcoholic Fatty Liver Disease in a Rat Model through Inhibition of Apoptosis and Enhancing Autophagy. Evid Based Complement Alternat Med (2013) 0.97
Leptin in hepatocellular carcinoma. World J Gastroenterol (2010) 0.93
[Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe (2010) 0.90
OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci (2014) 0.89
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr (2012) 0.89
Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus. J Obes (2010) 0.89
Imaging of non alcoholic fatty liver disease: A road less travelled. Indian J Endocrinol Metab (2013) 0.88
Correlation analysis between gene expression profile of rat liver tissues and high-fat emulsion-induced nonalcoholic fatty liver. Dig Dis Sci (2011) 0.87
Heme oxygenase-1 prevents non-alcoholic steatohepatitis through suppressing hepatocyte apoptosis in mice. Lipids Health Dis (2010) 0.86
A bioinformatic and mechanistic study elicits the antifibrotic effect of ursolic acid through the attenuation of oxidative stress with the involvement of ERK, PI3K/Akt, and p38 MAPK signaling pathways in human hepatic stellate cells and rat liver. Drug Des Devel Ther (2015) 0.86
Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol (2013) 0.85
Obesity-related cardiorenal disease: the benefits of bariatric surgery. Nat Rev Nephrol (2013) 0.83
Steatocholecystitis and fatty gallbladder disease. Dig Dis Sci (2008) 0.81
Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr (2010) 0.80
Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol (2012) 0.79
[Steatohepatitis after chemotherapy for colorectal liver metastases (CASH)]. Pathologe (2011) 0.79
Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant (2014) 0.78
Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. Hepat Med (2014) 0.77
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract (2016) 0.77
Effect of caloric restriction and AMPK activation on hepatic nuclear receptor, biotransformation enzyme, and transporter expression in lean and obese mice. Pharm Res (2013) 0.77
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Ann Gastroenterol (2016) 0.75
Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial. Adv Biomed Res (2015) 0.75
Sex differences in the association of HIV infection with hepatic steatosis. AIDS (2016) 0.75
Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD. J Proteome Res (2016) 0.75
Apoptosis and diagnosis of nonalcoholic steatohepatitis. Korean J Hepatol (2011) 0.75
Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Saudi J Gastroenterol (2016) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Alcoholic liver disease. Hepatology (2010) 5.04
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Alcoholic liver disease. Am J Gastroenterol (2009) 2.02
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 1.95
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc (2006) 1.59
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis (2002) 1.27
Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol (2004) 1.23
Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl (2009) 1.22
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
Measuring protein synthesis using metabolic ²H labeling, high-resolution mass spectrometry, and an algorithm. Anal Biochem (2011) 1.16
Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem (2010) 1.15
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol (2004) 1.13
Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol (2002) 1.12
Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol Cell Proteomics (2012) 1.05
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Gender differences in the regulation of amino acid metabolism. J Appl Physiol (1985) (2003) 1.03
Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol (2006) 1.02
Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol (2013) 1.01
Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int (2013) 1.00
Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol (2010) 0.99
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis (2012) 0.97
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci (2011) 0.94
Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci (2012) 0.92
Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int (2009) 0.91
Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis (2009) 0.90
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.89
Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. N Engl J Med (2006) 0.89
Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2013) 0.89
Future trends in hepatology: challenges and opportunities. Hepatology (2008) 0.89
Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. J Gastroenterol Hepatol (2014) 0.89
Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol (2012) 0.88
Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. Dig Dis Sci (2002) 0.88
Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans. Metabolism (2008) 0.88
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
Non-alcoholic fatty liver disease and obesity: not all about body mass index. Am J Gastroenterol (2012) 0.87
Inhibition of aromatase improves nutritional status following portacaval anastomosis in male rats. J Hepatol (2006) 0.85
Steroids or cocktails for alcoholic hepatitis. J Hepatol (2006) 0.85
The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis (2013) 0.85
Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2013) 0.84
Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease. Dig Dis Sci (2015) 0.83
Obesity and its nurturing effect on hepatitis C. Hepatology (2003) 0.81
Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio. Surg Obes Relat Dis (2011) 0.81
Differences in regulation of type I collagen synthesis in primary and passaged hepatic stellate cell cultures: the role of alpha5beta1-integrin. Am J Physiol Gastrointest Liver Physiol (2007) 0.81
Treatment of alcoholic hepatitis. Clin Liver Dis (2005) 0.78
An improved measurement of isotopic ratios by high resolution mass spectrometry. J Am Soc Mass Spectrom (2013) 0.78
Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients. Int Urol Nephrol (2013) 0.77
Obesity, hepatic metabolism and disease. Nestle Nutr Workshop Ser Pediatr Program (2009) 0.77
In Response. J Clin Gastroenterol (2016) 0.75
Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD. J Proteome Res (2016) 0.75
Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch anal anastomosis. J Crohns Colitis (2011) 0.75
Association between fatigue and decreased survival in primary biliary cirrhosis. Gut (2007) 0.75
How good is transjugular liver biopsy for the histological evaluation of liver disease? Nat Clin Pract Gastroenterol Hepatol (2007) 0.75
Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites. Gastroenterol Hepatol (N Y) (2011) 0.75
High prevalence of normal serum albumin in NASH patients with ascites: a retrospective analysis. Clin Res Hepatol Gastroenterol (2012) 0.75
The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue. Cell Rep (2017) 0.75
Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2017) 0.75
Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation. Eur J Gastroenterol Hepatol (2017) 0.75
The association of nonalcoholic steatohepatitis and obstructive sleep apnea. Eur J Gastroenterol Hepatol (2017) 0.75
Impact of De Novo and Preexisting Inflammatory Bowel Disease on the Outcome of Orthotopic Liver Transplantation. Inflamm Bowel Dis (2016) 0.75